Todd C. Brady M.D., Ph.D.
Net Worth

Last updated:

What is Todd C. Brady M.D., Ph.D. net worth?

The estimated net worth of Dr. Todd C. Brady M.D., Ph.D. is at least $18,094,889 as of 12 Mar 2024. He owns shares worth $8,115,680 as insider, has earned $580,809 from insider trading and has received compensation worth at least $9,398,400 in Aldeyra Therapeutics, Inc..

What is the salary of Todd C. Brady M.D., Ph.D.?

Dr. Todd C. Brady M.D., Ph.D. salary is $854,400 per year as Chief Executive Officer, Pres & Director in Aldeyra Therapeutics, Inc..

How old is Todd C. Brady M.D., Ph.D.?

Dr. Todd C. Brady M.D., Ph.D. is 53 years old, born in 1972.

What stocks does Todd C. Brady M.D., Ph.D. currently own?

As insider, Dr. Todd C. Brady M.D., Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Aldeyra Therapeutics, Inc. (ALDX) Chief Executive Officer, Pres & Director 1,471,298 $5.52 $8,115,680

What does Aldeyra Therapeutics, Inc. do?

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

ALDX logo
ALDX
Aldeyra Therapeutics, Inc.
$5.52

Todd C. Brady M.D., Ph.D. insider trading

Aldeyra Therapeutics, Inc.

Dr. Todd C. Brady M.D., Ph.D. has made 2 insider trades between 2014-2024, according to the Form 4 filled with the SEC. Most recently he sold 85,324 units of ALDX stock worth $260,238 on 12 Mar 2024.

The largest trade he's ever made was exercising 192,084 units of ALDX stock on 7 Sep 2023. As of 12 Mar 2024 he still owns at least 1,471,298 units of ALDX stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 85,324 $3.05 $260,238
Sale
Common Stock 97,914 $3.27 $320,570
Option
Common Stock 32,953 $0.55 $18,190
Option
Common Stock 48,021 $0.55 $26,508
Option
Stock Option (right to buy) 48,021 $0.55 $26,508
Option
Common Stock 192,084 $0.55 $106,030
Purchase
Common Stock 17,700 $3.36 $59,543
Purchase
Common Stock 20,000 $5.1 $101,900
Purchase
Common Stock 8,710 N/A N/A
Purchase
Common Stock 8,680 $5.81 $50,431
Purchase
Common Stock 14,288 N/A N/A
Purchase
Common Stock 6,000 $6.03 $36,180
Purchase
Common Stock 6,000 N/A N/A
Purchase
Common Stock 28,547 $5.84 $166,800
Purchase
Common Stock 28,547 $2.9 $82,644
Purchase
Common Stock 10,000 N/A N/A
Purchase
Common Stock 10,000 $5.39 $53,940
Purchase
Common Stock 22,223 $4.5 $100,004
Purchase
Common Stock 12,500 $8 $100,000

Aldeyra Therapeutics key executives

Aldeyra Therapeutics, Inc. executives and other stock owners filed with the SEC: